SCHEMBL3488154

SCHEMBL3488154

O=c1nc(-c2ccccc2)c2cc(C(F)(F)F)ccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ MEN1 O00255 2/20 0.64
▸ KMT2A Q03164 2/20 0.64
▸ CASP1 P29466 1/20 0.64
▸ NPSR1 Q6W5P4 1/20 0.64
▸ ALDH1A1 P00352 2/20 0.61
▸ HPGD P15428 2/20 0.61
▸ TSHR P16473 1/20 0.61
▸ PDE3B Q13370 1/20 0.54
▸ PDE3A Q14432 1/20 0.54
▸ KIF11 P52732 1/20 0.51
▸ MAP2K4 P45985 3/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ MAPKAPK3 Q16644 2/20 0.49
▸ MAPK6 Q16659 2/20 0.49
▸ NPBWR1 P48145 1/20 0.48
▸ MAPK13 O15264 2/20 0.47
▸ RAF1 P04049 2/20 0.47
▸ MAPK12 P53778 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11860404 0.89 KIF11 (0.56) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL11603400 0.81 KDM4E (0.69) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL17367218 0.81 KDM4E (0.73) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL11604874 0.78 KDM4E (0.69) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL6871615 0.78 KDM4E (1.00) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL11605848 0.78 KDM4E (0.69) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL5377653 0.78 MAP2K4 (0.73) KDM4EALDH1A1HPGDKIF11MAP2K4
SCHEMBL4142958 0.77 KDM4E (1.00) KDM4EHSD17B10MEN1KMT2ACASP1
Lithium SCHEMBL30669498 0.76 KDM4E (0.96) KDM4EHSD17B10MEN1KMT2ACASP1
SCHEMBL11459542 0.75 PDE3B (0.69) KDM4EHSD17B10MEN1KMT2ACASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2100507-B1 QUINAZOLINE DERIVATIVES CAPABLE OF INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL CO (JP) 2015-02-25 — — EP disclosed
US-8722580-B2 Agent for inhibiting cytokinin signaling SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-05-13 — — US disclosed
CN-101588716-B Substance capable of inhibiting cytokinin signaling SUMITOMO CHEMICAL CO 2014-03-05 — — CN disclosed
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-03-04 — — US disclosed
CN-101588716-A Substance capable of inhibiting cytokinin signaling SUMITOMO CHEMICAL CO (JP) 2009-11-25 — — CN disclosed
EP-2100507-A1 SUBSTANCE CAPABLE OF INHIBITING CYTOKININ SIGNALING Sumitomo Chemical Company, Limited (JP) 2009-09-16 — — EP disclosed
US-4202895-A 1-Polyhaloalkyl-2(1H)-quinazolinone derivatives SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-05-13 — — US disclosed
US-4067868-A Production of quinazolinone compounds SUMITOMO CHEMICAL COMPANY, LIMITED (JA) 1978-01-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056377-A1 AGENT FOR INHIBITING CYTOKININ SIGNALING CROCC, STAT3, GRK6 KDM4E 4572/4885HSD17B10 4139/4885MEN1 3850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback